InSite Vision

About InSite Vision

InSite Vision, founded in 1986, was a biopharmaceutical company focused on developing and commercializing ophthalmic products for diseases affecting the front and back of the eye. The company's core asset was its proprietary DuraSite® drug delivery technology, a polymer-based platform designed to extend the time a medication remains on the eye's surface. This key feature aimed to reduce dosing frequency for patients, potentially leading to better compliance and therapeutic outcomes compared to conventional topical eye drops.

The DuraSite platform was the foundation for InSite Vision's product pipeline and commercial activities. The company successfully brought two products to market, which were commercialized through partnerships: AzaSite®, for treating bacterial conjunctivitis (pink eye), and Besivance®, also for bacterial eye infections. Revenue was generated through these partnerships and licensing agreements. The company's business model centered on leveraging its delivery technology to create improved formulations of existing and new ophthalmic drugs, addressing a market that includes common conditions like eye infections, inflammation, and pain following cataract surgery. Over the years, InSite further developed its technology, introducing DuraSite 2, an enhanced version intended to improve drug retention and tissue penetration.

Throughout its history, InSite Vision operated as a publicly traded company, securing funding through various stages, including venture capital and a public offering in 1993. The company's journey culminated in a significant milestone in 2015 when it became the subject of a bidding process. After initially agreeing to a merger with QLT, InSite Vision received a superior, unsolicited offer from Sun Pharmaceutical Industries. In November 2015, Sun Pharma successfully completed the acquisition of InSite Vision for approximately $48 million, plus related debt. This transaction made InSite Vision an indirect wholly-owned subsidiary of Sun Pharma, integrating its late-stage clinical candidates and drug delivery technology into Sun Pharma's expanding branded ophthalmic portfolio in the United States.